Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ranjit Manchanda

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
Journal of Medical Genetics|March 20, 2016
Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutationsRanjit Manchanda, Matthew Burnell, Kelly Loggenberg, et al.
Journal of the National Cancer Institute|December 2, 2014
Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingRanjit Manchanda, Rosa Legood, Matthew Burnell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2021
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for <i>BRCA</i>1/2 variants in ovarian cancer in the United KingdomSudha Sundar, Ranjit Manchanda, Charlie Gourley, et al.
JAMA Oncology|October 4, 2019
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast CancerLi Sun, Adam Brentnall, Shreeya Patel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 15, 2022
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)Faiza Gaba, Karen Ash, Oleg Blyuss, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer PreventionLauren C Tindale, Almira Zhantuyakova, Stephanie Lam, et al.
Post Reproductive Health|October 11, 2024
British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancerAlexandra Taylor, Kathryn Clement, Timothy Hillard, et al.
Cancers|July 26, 2020
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal WomenAleksandra Gentry-Maharaj, Oleg Blyuss, Andy Ryan, et al.
Cancers|February 25, 2023
Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UKSamuel Oxley, Ashwin Kalra, Michail Sideris, et al.
The Lancet. Oncology|September 1, 2023
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trialUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
Journal of Medical Genetics|March 20, 2016
Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutationsRanjit Manchanda, Matthew Burnell, Kelly Loggenberg, et al.
Journal of the National Cancer Institute|December 2, 2014
Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingRanjit Manchanda, Rosa Legood, Matthew Burnell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2021
British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for <i>BRCA</i>1/2 variants in ovarian cancer in the United KingdomSudha Sundar, Ranjit Manchanda, Charlie Gourley, et al.
JAMA Oncology|October 4, 2019
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast CancerLi Sun, Adam Brentnall, Shreeya Patel, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 15, 2022
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)Faiza Gaba, Karen Ash, Oleg Blyuss, et al.
Current Oncology (Toronto, Ont.)|July 25, 2022
Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer PreventionLauren C Tindale, Almira Zhantuyakova, Stephanie Lam, et al.
Post Reproductive Health|October 11, 2024
British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancerAlexandra Taylor, Kathryn Clement, Timothy Hillard, et al.
Cancers|July 26, 2020
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal WomenAleksandra Gentry-Maharaj, Oleg Blyuss, Andy Ryan, et al.
Cancers|February 25, 2023
Impact of Multiple COVID-19 Waves on Gynaecological Cancer Services in the UKSamuel Oxley, Ashwin Kalra, Michail Sideris, et al.
The Lancet. Oncology|September 1, 2023
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trialUsha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, et al.
Pageof 14